EVX-01
Metastatic Melanoma
Phase 2Active
Key Facts
About Evaxion
Evaxion is a clinical-stage biotechnology company pioneering the use of artificial intelligence for vaccine discovery and development. Its core asset is the AI-Immunology™ platform, a suite of AI models designed to predict optimal vaccine targets for personalized cancer vaccines and next-generation infectious disease vaccines. The company has a pipeline of in-house assets ranging from preclinical to Phase 2 and is publicly traded on Nasdaq. Evaxion's approach aims to address significant unmet needs in oncology and antimicrobial resistance.
View full company profileTherapeutic Areas
Other Metastatic Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Supercarrier Prodrug | Temprian Oncology | Pre-clinical |
| ADZE1.C | Adze Biotechnology | Phase 1 |
| Opdualag (nivo + relatlimab) | Ono Pharmaceutical | Approved |
| APG-115 (Alrizomadlin) | Ascentage Pharma Group | Phase 2 |